Regulatory Affairs in Biopharmaceuticals

Regulatory Science is the science of advanced standards equipment, and paths to assess the safety, Drug toxicity and quality, potency of all FDA-regulated products. An access to lengthen the programs in regulatory science that leverages what has been well-educated in the development of training programs for translational scientists, and this model for regulatory science program development is being refined and adopted by all of the institutions that are part of the CTSA network. The target audience for such a program is broad, noted that it is necessary to break out of the mind-set that regulatory science resides totally with FDA and that the field's purpose is to create a workforce that will function within the FDA. Critical needs for a regulatory science training program understand research and scientific methodology, toxicology, therapeutics, and pharmacology that underpin the regulatory process.

  • Biopharma Regulatory challenges
  • Regulatory Approvals for Biopharma drug products
  • Overview of drug, biologic and device regulatory pathways
  • Role of Regulatory Authorities
  • BPCI Act
  • Hatch-Waxman Act

Related Conference of Regulatory Affairs in Biopharmaceuticals

July 27-28, 2026

19th World Drug Delivery Summit

Paris, France
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
April 27-28, 2027

10th European Biopharma Congress

Paris, France

Regulatory Affairs in Biopharmaceuticals Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in